Alterity Therapeutics Ltd (ATH) - Net Assets

Latest as of June 2025: AU$42.40 Million AUD ≈ $30.00 Million USD

Based on the latest financial reports, Alterity Therapeutics Ltd (ATH) has net assets worth AU$42.40 Million AUD (≈ $30.00 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$46.03 Million ≈ $32.57 Million USD) and total liabilities (AU$3.62 Million ≈ $2.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ATH cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$42.40 Million
% of Total Assets 92.13%
Annual Growth Rate N/A
5-Year Change 39.16%
10-Year Change 35.18%
Growth Volatility 80.58

Alterity Therapeutics Ltd - Net Assets Trend (1998–2025)

This chart illustrates how Alterity Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Alterity Therapeutics Ltd for the complete picture of this company's asset base.

Annual Net Assets for Alterity Therapeutics Ltd (1998–2025)

The table below shows the annual net assets of Alterity Therapeutics Ltd from 1998 to 2025. For live valuation and market cap data, see Alterity Therapeutics Ltd market cap and net worth.

Year Net Assets Change
2025-06-30 AU$42.40 Million
≈ $30.00 Million
+207.31%
2024-06-30 AU$13.80 Million
≈ $9.76 Million
-39.52%
2023-06-30 AU$22.81 Million
≈ $16.14 Million
-35.68%
2022-06-30 AU$35.47 Million
≈ $25.10 Million
+16.40%
2021-06-30 AU$30.47 Million
≈ $21.56 Million
+188.88%
2020-06-30 AU$10.55 Million
≈ $7.46 Million
-36.28%
2019-06-30 AU$16.55 Million
≈ $11.71 Million
+2.95%
2018-06-30 AU$16.08 Million
≈ $11.38 Million
-32.12%
2017-06-30 AU$23.69 Million
≈ $16.76 Million
-24.48%
2016-06-30 AU$31.37 Million
≈ $22.19 Million
-19.80%
2015-06-30 AU$39.11 Million
≈ $27.68 Million
+3.79%
2014-06-30 AU$37.69 Million
≈ $26.67 Million
+169.67%
2013-06-30 AU$13.97 Million
≈ $9.89 Million
+148.51%
2012-06-30 AU$5.62 Million
≈ $3.98 Million
-18.87%
2011-06-30 AU$6.93 Million
≈ $4.90 Million
+32.55%
2010-06-30 AU$5.23 Million
≈ $3.70 Million
+39.46%
2009-06-30 AU$3.75 Million
≈ $2.65 Million
-62.08%
2008-06-30 AU$9.89 Million
≈ $7.00 Million
+76.22%
2007-06-30 AU$5.61 Million
≈ $3.97 Million
-35.76%
2006-06-30 AU$8.73 Million
≈ $6.18 Million
-55.24%
2005-06-30 AU$19.51 Million
≈ $13.81 Million
-49.27%
2004-06-30 AU$38.47 Million
≈ $27.22 Million
+143.82%
2003-06-30 AU$15.78 Million
≈ $11.16 Million
-5.40%
2002-06-30 AU$16.68 Million
≈ $11.80 Million
-22.04%
2001-06-30 AU$21.39 Million
≈ $15.14 Million
+3.20%
2000-06-30 AU$20.73 Million
≈ $14.67 Million
+25796.43%
1999-06-30 AU$-80.67K
≈ $-57.08K
-11940.30%
1998-06-30 AU$-670.00
≈ $-474.07
--

Equity Component Analysis

This analysis shows how different components contribute to Alterity Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 22588868000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$262.95 Million 620.12%
Other Comprehensive Income AU$5.34 Million 12.60%
Total Equity AU$42.40 Million 100.00%

Alterity Therapeutics Ltd Competitors by Market Cap

The table below lists competitors of Alterity Therapeutics Ltd ranked by their market capitalization.

Company Market Cap
Global View Co Ltd
TW:3040
$80.80 Million
Vakrangee Limited
NSE:VAKRANGEE
$80.83 Million
Cayman Engley Industrial Co
TW:2239
$80.85 Million
Oil Terminal C
RO:OIL
$80.86 Million
Adyton Resources Corp
V:ADY
$80.71 Million
Magadh Sugar & Energy Limited
NSE:MAGADSUGAR
$80.70 Million
Ratchaphruek Hospital Public Company Limited
BK:RPH
$80.68 Million
Canterbury Park Holding Corporation
NASDAQ:CPHC
$80.67 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Alterity Therapeutics Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 13,798,057 to 42,403,086, a change of 28,605,029 (207.3%).
  • Net loss of 12,147,828 reduced equity.
  • Share repurchases of 42,570,650 reduced equity.
  • New share issuances of 42,570,645 increased equity.
  • Other comprehensive income increased equity by 536,101.
  • Other factors increased equity by 40,216,761.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-12.15 Million -28.65%
Share Repurchases AU$42.57 Million -100.4%
Share Issuances AU$42.57 Million +100.4%
Other Comprehensive Income AU$536.10K +1.26%
Other Changes AU$40.22 Million +94.84%
Total Change AU$- 207.31%

Book Value vs Market Value Analysis

This analysis compares Alterity Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.58x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1998-06-30 AU$0.00 AU$0.01 x
1999-06-30 AU$0.00 AU$0.01 x
2000-06-30 AU$0.63 AU$0.01 x
2001-06-30 AU$0.41 AU$0.01 x
2002-06-30 AU$0.31 AU$0.01 x
2003-06-30 AU$0.27 AU$0.01 x
2004-06-30 AU$0.52 AU$0.01 x
2005-06-30 AU$0.16 AU$0.01 x
2006-06-30 AU$0.07 AU$0.01 x
2007-06-30 AU$0.04 AU$0.01 x
2008-06-30 AU$0.06 AU$0.01 x
2009-06-30 AU$0.02 AU$0.01 x
2010-06-30 AU$0.02 AU$0.01 x
2011-06-30 AU$0.03 AU$0.01 x
2012-06-30 AU$0.02 AU$0.01 x
2013-06-30 AU$0.04 AU$0.01 x
2014-06-30 AU$0.09 AU$0.01 x
2015-06-30 AU$0.08 AU$0.01 x
2016-06-30 AU$0.06 AU$0.01 x
2017-06-30 AU$0.04 AU$0.01 x
2018-06-30 AU$0.03 AU$0.01 x
2019-06-30 AU$0.03 AU$0.01 x
2020-06-30 AU$0.01 AU$0.01 x
2021-06-30 AU$0.02 AU$0.01 x
2022-06-30 AU$0.01 AU$0.01 x
2023-06-30 AU$0.01 AU$0.01 x
2024-06-30 AU$0.00 AU$0.01 x
2025-06-30 AU$0.01 AU$0.01 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Alterity Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -28.65%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -223.35%
  • • Asset Turnover: 0.12x
  • • Equity Multiplier: 1.09x
  • Recent ROE (-28.65%) is above the historical average (-67.40%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1998 0.00% 0.00% 0.00x 0.00x AU$-623.00
1999 0.00% 0.00% 0.00x 0.00x AU$-71.93K
2000 -6.40% -1684.00% 0.00x 1.01x AU$-3.40 Million
2001 -19.35% -801.84% 0.02x 1.04x AU$-6.28 Million
2002 -32.69% -686.23% 0.05x 1.05x AU$-7.12 Million
2003 -28.97% -252.40% 0.11x 1.04x AU$-6.15 Million
2004 -25.54% -425.88% 0.06x 1.07x AU$-13.67 Million
2005 -127.63% -942.61% 0.12x 1.14x AU$-26.86 Million
2006 -134.25% -1537.92% 0.07x 1.19x AU$-12.60 Million
2007 -198.54% -2197.05% 0.07x 1.38x AU$-11.70 Million
2008 -137.44% -2762.17% 0.04x 1.19x AU$-14.58 Million
2009 -200.62% -1756.87% 0.09x 1.23x AU$-7.90 Million
2010 -93.83% -2282.20% 0.03x 1.30x AU$-5.43 Million
2011 -92.79% -4118.99% 0.02x 1.30x AU$-7.12 Million
2012 -93.17% -2806.90% 0.03x 1.31x AU$-5.80 Million
2013 -55.72% -5161.66% 0.01x 1.22x AU$-9.18 Million
2014 -35.37% -3664.14% 0.01x 1.10x AU$-17.10 Million
2015 -15.05% -3327.87% 0.00x 1.07x AU$-9.80 Million
2016 -24.64% -5418.28% 0.00x 1.08x AU$-10.87 Million
2017 -31.84% -5696.60% 0.01x 1.07x AU$-9.91 Million
2018 -51.40% -4108.75% 0.01x 1.16x AU$-9.87 Million
2019 -72.26% -11020.84% 0.01x 1.20x AU$-13.62 Million
2020 -95.37% -58759.84% 0.00x 1.26x AU$-11.11 Million
2021 -50.24% -352.78% 0.13x 1.10x AU$-18.36 Million
2022 -36.22% -250.75% 0.12x 1.17x AU$-16.39 Million
2023 -60.52% -352.54% 0.14x 1.20x AU$-16.09 Million
2024 -138.60% -475.79% 0.21x 1.39x AU$-20.50 Million
2025 -28.65% -223.35% 0.12x 1.09x AU$-16.39 Million

Industry Comparison

This section compares Alterity Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $4,124,708
  • Average return on equity (ROE) among peers: -349.73%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Alterity Therapeutics Ltd (ATH) AU$42.40 Million 0.00% 0.09x $80.80 Million
Adalta Ltd (1AD) $705.89K -185.28% 0.37x $8.12 Million
Algorae Pharmaceuticals Ltd (1AI) $8.43 Million -80.40% 0.15x $20.04 Million
ACRUX Ltd (ACR) $3.28 Million -177.05% 1.74x $3.49 Million
Actinogen Medical Ltd (ACW) $346.99K -440.69% 0.34x $103.45 Million
Argenica Therapeutics Ltd (AGN) $18.40K -2084.05% 19.53x $15.45 Million
Arovella Therapeutics Ltd (ALA) $15.99 Million -12.83% 0.27x $66.62 Million
Anatara Lifesciences Ltd (ANR) $-280.65K 0.00% 0.00x $1.57 Million
Amplia Therapeutics Ltd (ATX) $5.98 Million -67.99% 0.37x $54.45 Million
Avecho Biotechnology Ltd (AVE) $2.65 Million -99.27% 0.26x $31.19 Million

About Alterity Therapeutics Ltd

AU:ATH Australia Biotechnology
Market Cap
$80.80 Million
AU$114.19 Million AUD
Market Cap Rank
#20010 Global
#683 in Australia
Share Price
AU$0.01
Change (1 day)
+5.00%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$0.17
About

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-… Read more